Comparative study the use of metformin versus placebo for prophylaxis from gestational diabetes in high risk patients
Not Applicable
Not yet recruiting
- Conditions
- Nutritional, Metabolic, EndocrinePregnancy and Childbirthgestational diabetes
- Registration Number
- PACTR201503001059248
- Lead Sponsor
- Tamer Mamdouh Abdel Dayem
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Female
- Target Recruitment
- 300
Inclusion Criteria
i.Obese patients with body mass index above 30.
ii.Patients with history of gestational diabetes.
iii.Patients with history of gestational diabetes in previous pregnancies.
iv.Patients with multiple gestation.
v.Pateints with family history of gestational diabetes in siblings or type 2 diabetes in parents.
vi.Patients with polycystic ovarian disease
Exclusion Criteria
1-Patients with pre-gestational diabetes
2-Patients with intolerance to metformin e.g. hypersensitivity to the medication.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie metformin's preventive effects on gestational diabetes in high-risk patients?
How does metformin compare to standard-of-care interventions in preventing gestational diabetes in high-risk populations?
Which biomarkers are associated with metformin response in high-risk gestational diabetes prevention?
What are the potential adverse events of metformin use for gestational diabetes prophylaxis and their management strategies?
Are there combination therapies or alternative drugs to metformin for gestational diabetes prevention in high-risk patients?